One option might be to wait and see if semaglutides cause side-effects (since, if my understanding is correct, the primary reason that the Phase 3 trials of Invex’s main asset, Presendin, were stopped was due to semaglutides being used for weight loss across a large proportion of the potential user base for Presendin which consequently reduced the severity/frequency of conditions involving raised intracranial pressure).
For example, here is an article from the American Academy of Opthalmology, regarding potential (as yet unconfirmed) links between semaglutide usage and increased risk for the blinding eye disease non-arteritic ischemic optic neuropathy (NAION):
https://www.aao.org/eye-health/news/can-ozempic-affect-eye-health-here-s-what-ophthalm
- Forums
- ASX - By Stock
- Ann: Change in substantial holding
One option might be to wait and see if semaglutides cause...
Featured News
Add IXC (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.411M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 29320 | 7.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 29320 | 0.070 |
1 | 100000 | 0.066 |
1 | 100000 | 0.065 |
1 | 84879 | 0.063 |
2 | 158500 | 0.060 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 10000 | 1 |
0.080 | 5000 | 1 |
0.090 | 126146 | 1 |
0.095 | 100000 | 1 |
0.100 | 8505 | 2 |
Last trade - 16.12pm 27/08/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online